Sterling Biotech is currently trading at Rs 8.26, up by 0.85 points or 11.47% from its previous closing of Rs 7.41 on the BSE.
The scrip opened at Rs 8.50 and has touched a high and low of Rs 8.89 and Rs 7.60 respectively. So far 2481451 shares were traded on the counter.
The BSE group 'B' stock of face value Re 1 has touched a 52 week high of Rs 8.20 on 09-Jan-2013 and a 52 week low of Rs 3.43 on 20-Mar-2013.
Last one week high and low of the scrip stood at Rs 7.41 and Rs 5.06 respectively. The current market cap of the company is Rs. 221.26 crore.
The promoters holding in the company stood at 33.91% while Institutions and Non-Institutions held 9.10% and 40.12% respectively.
Sterling Biotech’s existing Bond Holders at its meeting held on November 20, 2013, have approved for the conversion price of the Bonds, due 2018 to be at Rs. 60 per share, subject to Reserve Bank of India, Foreign Investment Promotion Board and such other regulatory approvals, if any, as may be required;
The Bond holders have also approved to suspend all litigations in India and UK till January 2014 and to withdraw the litigations in India and UK on completion of the exchange and substitution of the Existing Bonds with and for the Zero Coupon Convertible Bonds due 2018.
Sterling Biotech is largest producer of pharmaceutical and nutraceutical gelatin in India and Asia as well. It has a 9.3% global market share in pharmaceutical gelatin and is among the top five gelatin producers globally.
| Company Name | CMP |
|---|---|
| BASF India | 3703.10 |
| Tata Chemicals | 709.05 |
| SRF | 2493.65 |
| Pidilite Inds. | 1393.25 |
| Deepak Nitrite | 1538.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: